Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.

被引：0
|
作者：
Khalid, Farhan
Kashyap, Richi
Singh, Vinit
Tayyeb, Muhammad
Jaan, Ali
Mohan, Gaurav
Meghal, Trishala
机构：
[1] Monmouth Med Ctr, Dept Internal Med, Long Branch, NJ USA
[2] North Alabama Med Ctr, Dept Internal Med, Florence, AL USA
[3] Rochester Gen Hosp, Dept Internal Med, Rochester, NY USA
[4] Monmouth Med Ctr, Dept Med, Sect Hematol, Long Branch, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13068
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sacituzumab govitecan in triple-negative breast cancer
    de Nonneville, Alexandre
    Goncalves, Anthony
    Mamessier, Emilie
    Bertucci, Francois
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [2] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [3] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
  • [4] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
  • [5] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [6] Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials
    Perez-Bermejo, Marcelino
    Caballero-Pascual, Monica
    Legidos-Garcia, Maria Ester
    Martinez-Peris, Miriam
    Casana-Mohedo, Jorge
    Llorca-Colomer, Francisco
    Ventura, Ignacio
    Tomas-Aguirre, Francisco
    Asins-Cubells, Adalberto
    Murillo-Llorente, Maria Teresa
    CANCERS, 2024, 16 (21)
  • [7] The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    Michaleas, S.
    Oliver, A. Moreno
    Mueller-Berghaus, J.
    Sarac, S. B.
    van der Elst, M. E.
    Mueller-Egert, S.
    Zander, H.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2022, 7 (03)
  • [8] Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (12) : 1271 - 1271
  • [9] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
  • [10] Sacituzumab govitecan-a new therapy for patients with triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 43 - 49
12345